rs16989673 — PTPN1 1484insG

A guanine duplication in the 3'-UTR of PTPN1 (PTP1B) that increases mRNA stability and skeletal muscle PTP1B expression, amplifying negative regulation of the insulin receptor and contributing to insulin resistance.

See your personal result for PTPN1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PTPN1 1484insG — The Insulin Signal Off-Switch That Stays On Too Long

Every time insulin docks to its receptor on a muscle or liver cell, a molecular stopwatch starts. A phosphatase called PTP1B11 PTP1B
protein tyrosine phosphatase non-receptor type 1, encoded by PTPN1 is assigned to flip the off-switch: it strips phosphate groups from the activated insulin receptor, ending the signal. The 1484insG variant in the 3'-UTR of PTPN1 makes more PTP1B protein — meaning the off-switch fires sooner and more forcefully than it should, leaving the insulin receptor under-stimulated.

The Mechanism

The 1484insG variant is a single guanine duplication (G→GG) located 104 nucleotides downstream of the PTP1B stop codon in the 3' untranslated region. It does not change the protein sequence — instead, it changes how long the mRNA survives in the cell.

The foundational study by Di Paola et al.22 Di Paola et al.
A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. AJHG, 2002 demonstrated two effects in carriers: (1) skeletal muscle PTP1B mRNA levels were roughly twice as high (6,166 vs 2,983 copies/40 ng RNA, p<0.01), and (2) mRNA stability was significantly greater in HEK293 cells transfected with the 1484insG construct compared to wild-type (p<0.01). The interpretation is that the insertion disrupts an AU-rich element or destabilising motif in the 3'-UTR that normally limits mRNA half-life, allowing more transcript to accumulate and be translated into PTP1B protein.

PTP1B sits at the apex of a key negative feedback loop: after insulin activates its receptor's tyrosine kinase domain, the receptor auto-phosphorylates and phosphorylates IRS-1, initiating the PI3K → Akt → GLUT4 cascade that drives glucose uptake. PTP1B directly dephosphorylates both the insulin receptor and IRS-1, terminating this cascade. Elevated PTP1B — whether from 1484insG or from obesity-induced upregulation — blunts insulin sensitivity at the very first step.

The Evidence

The Di Paola study of 335 Sicilian subjects found that 1484insG carriers showed higher HOMA-IR (a proxy for insulin resistance, p=0.006), elevated triglycerides (p=0.0002), and a higher total/HDL cholesterol ratio (p=0.025) in males. Female carriers had elevated blood pressure (p=0.01). Allele frequency in this Italian cohort was approximately 5%.

An independent Iranian case-control study Meshkani et al. 200733 Meshkani et al. 2007
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population. Arch Med Res (n=696) confirmed the insulin resistance association in non-diabetic males (fasting insulin p=0.003, HOMA-IR p=0.011, LDL-C p=0.037, apoB p=0.015) though it did not detect significant differences in a diabetic subgroup. The insertion allele frequency was 4.1–4.9% in this Middle Eastern cohort, compared to ~7–8% in Europeans.

A larger Florez et al. study 200544 2005
Association testing of PTPN1 with type 2 diabetes in 7,883 people. Diabetes found no statistically significant association between PTPN1 SNPs and overt type 2 diabetes diagnosis, suggesting that 1484insG acts primarily on continuous metabolic traits (insulin levels, HOMA-IR, lipids) rather than pushing directly to frank diabetes — consistent with a moderate-penetrance risk modifier rather than a high-effect diabetes gene.

The PTP1B-inhibition angle has therapeutic support: berberine, a plant alkaloid used in metabolic conditions, has been shown to directly inhibit PTP1B phosphatase activity55 directly inhibit PTP1B phosphatase activity
Chen et al. BBRC 2010 in adipocytes and myocytes, increasing insulin receptor phosphorylation and lowering blood glucose in diabetic mice — providing a pharmacological proof of concept that elevated PTP1B is actionable.

Practical Actions

The 1484insG variant's effect is expressed primarily as elevated insulin resistance markers (fasting insulin, HOMA-IR) and dyslipidemia — particularly elevated triglycerides and LDL-C. Monitoring these markers directly tracks the phenotype this variant drives. Berberine's documented PTP1B-inhibiting activity makes it a mechanistically targeted supplement for carriers. Reducing dietary refined carbohydrates lowers the postprandial insulin burden on cells with impaired signaling amplification.

Interactions

PTPN1 1484insG operates at the top of the insulin receptor signaling cascade and interacts with downstream variants. ENPP1 K121Q (rs1044498) independently inhibits insulin receptor activation by physical binding, creating a dual upstream block when combined with elevated PTP1B from 1484insG. IRS-1 Gly972Arg (rs2943641) impairs the primary phosphorylation substrate of the activated receptor; combined with PTP1B overexpression, the PI3K/Akt pathway faces a compounded bottleneck. TCF7L2 rs7903146 (T allele) affects beta-cell incretin response and glucose metabolism further downstream; its combination with upstream insulin signaling impairment is a proposed compound pathway for early metabolic dysfunction.

Nutrient Interactions

glucose altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

DD Standard PTP1B Activity Normal

Normal PTPN1 expression — insulin receptor signal terminates on schedule

The wild-type 3'-UTR sequence contains regulatory elements that limit PTPN1 mRNA half-life to physiological levels. PTP1B is still expressed and performs its normal role in insulin receptor signal termination — it is a physiological regulator, not absent — but at normal activity levels. Baseline metabolic risk in this genotype is driven by diet, body composition, physical activity, and other genetic variants rather than PTPN1 itself.

DI Elevated PTP1B Activity Intermediate

One insertion allele — moderately increased PTPN1 expression

The 1484insG insertion disrupts a 3'-UTR destabilising motif, increasing mRNA stability roughly 2-fold in cell-based assays. Heterozygotes carry one normal and one hyperactive allele — expected to produce intermediate PTP1B elevation. The Di Paola 2002 cohort documented significantly higher HOMA-IR (p=0.006), triglycerides (p=0.0002), and total/HDL ratio (p=0.025) in heterozygous males. The Meshkani 2007 Iranian cohort confirmed insulin resistance in non-diabetic heterozygous males (HOMA-IR p=0.011). The variant did not predict overt T2DM diagnosis in the larger Florez 2005 study (n=7,883), consistent with moderate-penetrance trait modification rather than a high-effect diabetes SNP.

II High PTP1B Activity High Risk

Two insertion alleles — substantially increased PTPN1 expression and insulin resistance

II homozygotes face PTP1B elevation from both alleles simultaneously. While direct clinical data on II homozygotes is limited due to their rarity, the established mechanism (mRNA stabilisation → elevated protein → faster insulin receptor dephosphorylation) predicts the strongest phenotype. The heterozygous findings in Di Paola 2002 and Meshkani 2007 — elevated HOMA-IR, triglycerides, LDL-C, and apoB — would be expected to be amplified in II carriers. ClinVar formally classifies rs16989673 as a risk factor for insulin resistance susceptibility based on the 2002 AJHG study.

Berberine, which directly inhibits PTP1B phosphatase activity, is a mechanistically targeted approach. Strategies that engage insulin-independent glucose uptake (muscle contraction-driven GLUT4 translocation) also directly bypass the impaired receptor signaling.